StreetAlpha
13F holdings · Q3 2026

Enavate Sciences Gp

New York, NY · files as Enavate Sciences Gp, LLC
Know the moment Enavate Sciences Gp filesYou follow Enavate Sciences Gp An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1953107

Enavate Sciences Gp reported 8 stocks worth $280M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ZBIO (28.1%), IMNM (27.8%) and BRVE (26.5%). Compared with Q2 2026, the fund opened new positions in BRVE and trimmed ZBIO and CAMP.

Latest filing: what Enavate Sciences Gp did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
1 new0 added2 trimmed0 sold outBought about $74.2M · sold about $28.5M
New 1
Added 0

None

Trimmed 2
Sold out 0

None

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$280M−19.0% vs last quarter
Stocks held81 new · 0 sold out
Top 5 weight91.8%very concentrated
Turnover37%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
ZBIO
Zenas Biopharma Inc
$78.7M28.1%2.9M−1M (−26%)8 of 8
2
IMNM
Immunome Inc
$77.7M27.8%3.6MNo change8 of 8
3
BRVE
Braveheart Bio Inc
$74.2M26.5%3.7MNew position1 of 8
4
SION
Sionna Therapeutics Inc
$13M4.7%2.5MNo change7 of 8
5
UPB
Upstream Bio Inc
$13M4.6%2.5MNo change8 of 8
6
BBOT
Bridgebio Oncology Therapeut
$10.8M3.9%2.6MNo change5 of 8
7
CMPX
Compass Therapeutics Inc
$8.1M2.9%7.8MNo change8 of 8
8
CAMP
CAMP4 Therapeutics Corp
$4.2M1.5%1M−384K (−27%)8 of 8

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Reported value

last 8 quarters
$139MQ4 '24
$133MQ1 '25
$177MQ2 '25
$328MQ3 '25
$507MQ4 '25
$352MQ1 '26
$345MQ2 '26
$280MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Enavate Sciences Gp 13F FAQ

What does Enavate Sciences Gp own?

Enavate Sciences Gp reported 8 stocks worth $280M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ZBIO (28.1%), IMNM (27.8%) and BRVE (26.5%). The table above lists every position in the filing (the top 10 without an account).

What did Enavate Sciences Gp buy and sell in Q3 2026?

Compared with Q2 2026: 1 new positions, 0 added to, 2 trimmed and 0 sold out. New positions include BRVE.

When will Enavate Sciences Gp file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Enavate Sciences Gp's portfolio worth?

The Q3 2026 filing reports $280M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.